Vanda Pharmaceuticals has unveiled that the FDA has approved NEREUS™ (tradipitant), a new treatment to prevent vomiting caused by motion sickness. This is the first new medicine for motion sickness in over 40 years and is a major breakthrough in understanding as well as treating this common condition.
The approval is based on results from three important clinical trials, where NEREUS™ significantly reduced vomiting compared to a placebo. In these trials, people who used NEREUS™ had much lower vomiting rates, with reductions of over 50-70%.
Motion sickness has been a long-standing issue, especially in military settings. In fact, it was a serious problem during World War II, notably during the D-Day invasion in 1944, where it affected troops' performance. This led to early research into treatments for motion sickness.
Now, with the FDA approval of NEREUS™, Vanda plans to explore other potential uses for tradipitant, including treating conditions like gastroparesis (a stomach disorder) and nausea caused by certain obesity and diabetes medications.
Executive Statement
According to Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals, this approval underscores the strong scientific evidence in the antiemetic effects of NEREUS™ in motion sickness. For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options. They are proud of this historic milestone and grateful to the Vanda researchers, patients, investigators, and regulators who contributed to this achievement.
